The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains

Retrovirology

Volumn 8, Issue , 2011, Pages

  Mbisa, Jean L ^a   Gupta, Ravi K ^b   Kabamba, Desire ^c   Mulenga, Veronica ^c   Kalumbi, Moxmalama ^c   Chintu, Chifumbe ^c   Parry, Chris M ^a   Gibb, Diana M ^d   Walker, Sarah A ^d   Cane, Patricia A ^a   Pillay, Deenan ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY TEACHING HOSPITAL   (Zambia)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; GLUTAMINE; ISOLEUCINE; LAMIVUDINE; METHIONINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; VALINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CASE REPORT; CELL STRAIN HEK293; CODON; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; VIRUS GENOME; VIRUS REPLICATION; WILD TYPE; ADAPTATION; AMINO ACID SUBSTITUTION; DNA SEQUENCE; DRUG EFFECT; GENETICS; MISSENSE MUTATION; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADAPTATION, BIOLOGICAL; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; EVOLUTION, MOLECULAR; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; VIRUS REPLICATION;

EID: 79955760451     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-31     Document Type: Article

References (46)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2009, 1-161. 20-7-2010, Panel on Antiretroviral Guidelines for Adults and Adolescents.
2. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-570.
3. World Health Organization (WHO) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2010, 20-7-2010, World Health Organization (WHO).
4. Ren J, Stammers DK. HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. Trends Pharmacol Sci 2005, 26:4-7.
5. Sarafianos SG, Das K, Ding J, Boyer PL, Hughes SH, Arnold E. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem Biol 1999, 6:R137-R146.
6. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790.
7. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282:1669-1675.
8. Menendez-Arias L, Martinez MA, Quinones-Mateu ME, Martinez-Picado J. Fitness variations and their impact on the evolution of antiretroviral drug resistance. Curr Drug Targets Infect Disord 2003, 3:355-371.
9. Harada S, Hazra R, Tamiya S, Zeichner SL, Mitsuya H. Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in children receiving long-term antiretroviral chemotherapy. Antiviral Res 2007, 75:159-166.
10. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008, 10:67-84.
11. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995, 92:2398-2402.
12. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996, 70:1086-1090.
13. Garcia-Lerma JG, Gerrish PJ, Wright AC, Qari SH, Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J Virol 2000, 74:9339-9346.
14. Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol 1999, 73:5356-5363.
15. Matsumi S, Kosalaraksa P, Tsang H, Kavlick MF, Harada S, Mitsuya H. Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants. AIDS 2003, 17:1127-1137.
16. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009, 23:1127-1134.
17. Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS 2003, 17:1889-1896.
18. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007, 44:447-452.
19. Gupta RK, Ford D, Mulenga V, Walker AS, Kabamba D, Kalumbi M, et al. Drug Resistance in Human Immunodeficiency Virus Type-1 Infected Zambian Children Using Adult Fixed Dose Combination Stavudine, Lamivudine, and Nevirapine. Pediatr Infect Dis J 2010,
20. Delviks-Frankenberry KA, Nikolenko GN, Pathak VK. The "Connection" Between HIV Drug Resistance and RNase H. Viruses 2010, 2:1476-1503.
21. Ehteshami M, Gotte M. Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev 2008, 10:224-235.
22. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007, 4:e335.
23. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, Hughes SH, Coffin JM, Jere A, et al. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci USA 2008, 105:10943-10948.
24. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. J Virol 2007, 81:6837-6845.
25. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA 2005, 102:2093-2098.
26. Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCormick S, Wynhoven B, et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008, 283:22222-22232.
27. Gotte M. Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing. PLoS Med 2007, 4:e346.
28. Gallego O, Mendoza C, Labarga P, Altisent C, Gonzalez J, Garcia-Alcalde I, et al. Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes. HIV Clin Trials 2003, 4:372-381.
29. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010, 18:156-163.
30. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44:920-928.
31. Barnas D, Koontz D, Bazmi H, Bixby C, Jemsek J, Mellors JW. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir. Antivir Ther 2010, 15:437-441.
32. Delviks-Frankenberry KA, Nikolenko GN, Maldarelli F, Hase S, Takebe Y, Pathak VK. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine. J Virol 2009, 83:8502-8513.
33. Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, et al. Tenofovir resistance and resensitization. Antimicrob Agents Chemother 2003, 47:3478-3484.
34. Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 2001, 20:1025-1028.
35. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15:4040-4049.
36. Wei X, Liang C, Gotte M, Wainberg MA. Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 2003, 311:202-212.
37. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006, 19:1-7.
38. Shafer RW, Winters MA, Iversen AK, Merigan TC. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrob Agents Chemother 1996, 40:2887-2890.
39. Maeda Y, Venzon DJ, Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998, 177:1207-1213.
40. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005, 43:406-413.
41. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:1596-1599.
42. Parry CM, Kohli A, Boinett CJ, Towers GJ, McCormick AL, Pillay D. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol 2009, 83:9094-9101.
43. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. Full-length HIV-1 Gag determines protease inhibitor. AIDS 2010, 24:1651-1655.
44. Bainbridge JW, Stephens C, Parsley K, Demaison C, Halfyard A, Thrasher AJ, et al. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther 2001, 8:1665-1668.
45. Besnier C, Takeuchi Y, Towers G. Restriction of lentivirus in monkeys. Proc Natl Acad Sci USA 2002, 99:11920-11925.
46. Wright E, Temperton NJ, Marston DA, McElhinney LM, Fooks AR, Weiss RA. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol 2008, 89:2204-2213.